Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

EvoXRare AI-Assisted Interpretation of Emergency Chest Radiographs (CXR-AI-RCT)

EvoXRare-Assisted Chest Radiograph Interpretation in Emergency and Critically Ill Adults: A Nationwide Multicenter Randomized Controlled Trial

Chest radiography is widely used in emergency departments, resuscitation rooms, intensive care units, and other acute-care settings. Clinically important abnormalities may be missed because findings are subtle, uncommon, obscured by overlapping anatomy, or encountered under high workload. This pragmatic randomized trial evaluates whether EvoXRare, an artificial intelligence system that provides a draft chest radiograph report and high-risk alerts for uncommon or clinically important abnormalities, reduces clinically important diagnostic misses compared with routine physician interpretation alone. Approximately 70,000 adults will be randomized 1:1 across 15-20 hospitals in China. The primary endpoint is the patient-level rate of clinically important abnormalities present on the reference standard but not reported in the initial clinical interpretation. Key secondary outcomes include detection of rare or easily missed findings, time to recognition of critical abnormalities, report turnaround time, false-positive alerts, additional imaging, recall/communication events, and selected short-term clinical outcomes.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

This is a nationwide, multicenter, prospective, parallel-group, superiority randomized controlled trial with individual participant-level 1:1 allocation and blinded central endpoint adjudication. Eligible participants are adults undergoing clinically indicated chest radiography in emergency or critical-care settings. Only one index radiograph encounter per participant contributes to the primary randomized analysis.

In the control arm, physicians interpret the chest radiograph using the participating hospital's usual workflow without access to EvoXRare trial output. In the intervention arm, EvoXRare processes the same image on an independent AI workstation and provides a pre-generated report and/or high-risk prompts. The physician must review the original image, verify or edit the AI output, and remains responsible for the final report and all clinical communication. Both arms retain routine senior review and local critical-result procedures.

The AI model version, weights, preprocessing, thresholds, supported finding set, and report format are frozen before formal enrollment. No online learning or outcome-driven recalibration occurs during the randomized trial. If AI processing fails or images do not meet technical requirements, clinical care proceeds without delay and the participant remains in the assigned group for intention-to-treat analysis.

The reference standard is established by a blinded adjudication process using the index radiograph together with clinically available follow-up information, which may include subsequent CT, ultrasound, pathology, surgery, laboratory findings, clinical course, discharge diagnosis, or follow-up imaging. Adjudicators do not use the randomized assignment or EvoXRare output when determining whether a prespecified abnormality was present on the index radiograph.

The trial is designed primarily to test clinical diagnostic performance and workflow impact, not to retrain the AI system. It specifically emphasizes uncommon, high-consequence, and easily missed chest radiograph findings while also evaluating overall report quality and efficiency.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

70000

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Xiaoyu Han, PhD
  • Número de teléfono: +86 18202771604
  • Correo electrónico: xiaoyuhan1123@163.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 90 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age 18 years or older.
  • Undergoing a clinically indicated chest radiograph in a participating emergency department, resuscitation room, intensive care unit, or other prespecified acute/critical-care setting.
  • Chest radiograph is technically accessible to the study workflow before or during routine clinical interpretation.
  • The participant has not previously been randomized in this trial, unless the final protocol explicitly permits a separate recurrent-encounter analysis that does not enter the primary endpoint.
  • Consent or ethics-approved waiver/alteration of consent is satisfied according to the activated site protocol.

Exclusion Criteria:

  • Age younger than 18 years.
  • Image is missing, corrupted, or technically non-diagnostic to a degree that prevents clinical interpretation.
  • Radiograph was obtained solely for research rather than clinical care.
  • AI processing cannot be initiated because the image format or transfer route is outside the locked system specification; such cases may be recorded in screening logs but are not randomized unless the protocol allows post-randomization technical failure.
  • Prior randomization of the same participant in this trial for the primary participant-level analysis.
  • Any local legal, ethical, or institutional restriction that prevents study participation or required data use.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: EvoXRare AI-Assisted Chest Radiograph Interpretation.

Usual chest radiograph interpretation plus access to EvoXRare-generated draft report and high-risk prompts. The physician reviews the original image, accepts/rejects/edits AI suggestions, submits the final report, and follows local critical-result communication procedures.

EvoXRare is an artificial intelligence software system that analyzes chest radiographs and provides draft reports and high-risk prompts to the interpreting physician. The physician reviews the original images and AI outputs and accepts, rejects, or edits the suggestions before finalizing the radiology report.

Sin intervención: No Intervention / Active usual-care comparator: Standard Chest Radiograph Interpretation.

Routine physician interpretation according to the participating hospital's usual workflow, without access to EvoXRare trial output. Routine nontrial tools already in use may continue only if documented before site activation and applied consistently.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Patient-Level Clinically Important Abnormality Miss Rate on the Index Chest Radiograph
Periodo de tiempo: From index radiograph interpretation through completion of blinded endpoint adjudication, using clinically available information obtained during the index encounter and prespecified follow-up window (target: within 30 days when available).

Proportion of randomized participants with at least one prespecified clinically important abnormality (Category A or B) judged present on the reference standard but absent from the initial finalized chest radiograph report produced under the assigned strategy.

From index radiograph interpretation through completion of blinded endpoint adjudication, using clinically available information obtained during the index encounter and prespecified follow-up window (target: within 30 days when available).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de noviembre de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2028

Fechas de registro del estudio

Enviado por primera vez

3 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Publicado por primera vez (Actual)

9 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • WHUH-CXR-AI-RCT-2026-11

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Yes, through controlled access subject to compatible consent/ethics approval and institutional authorization.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .